3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
55
Recurrence
6
Neoplasms, Plasma Cell
3
Plasmacytoma
2
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Immunoglobulin Light-chain Amyloidosis
2
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Various Advanced Cancer
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Smoldering Multiple Myeloma
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Personal Satisfaction
1
Patient Satisfaction
1
Patient Preference
1
Pancreatic Neoplasms
1
Non-small Cell Lung Cancer With STK11/LKB1 Mutation
1
Myelodysplastic Syndromes
1
Microsatellite Unstable Colorectal Cancer
1
Lymphoma
1
Leukemia, Myeloid
1
Leukemia, Monocytic, Acute
1
Hodgkin Disease
1
Carcinoma, Renal Cell
1
Amyloidosis
1
Acute Kidney Injury
1
Interventions
Nivolumab
4
Ipilimumab
3
relatlimab
1
daratumumab
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Various Advanced Cancer
×
daratumumab
×
Clear all
NCT02488759
2023-11-13
CheckMate358
Bristol-Myers Squibb
Phase 1/2
Completed
578 enrolled
19 charts